Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025
Cost of revenue grows 124.5% year over year
Q4 FY2025 cost of revenue of $876.72K rose 124.5% year over year. Over 3 fiscal years it compounded at -51.6% a year.
Context
- Cost of revenue amounted to 12.8% of revenue in FY2025, down 15.3 pp from a year earlier.
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.25M USD
- Year-over-year change
- -45.8%
- 4-year CAGR
- -9.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.25M | -45.8% |
| FY2024 | 2024-12-31 | 2.3M | -31.4% |
| FY2023 | 2023-12-31 | 3.35M | -69.5% |
| FY2022 | 2022-12-31 | 10.98M | +482.1% |
| FY2021 | 2021-12-31 | 1.89M | — |
Cost of Revenue vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -45.8% is the lowest of 8, against a peer median of +18.2%.
- Cost of revenue amounts to 12.8% of revenue for NNNN, versus a peer median of 46.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.96B USD | +35.0% | +16.0% | 46.3% | |
| LTM Mar 2026 | CA$682.57M CAD | +0.2% | +6.3% | 72.8% | |
| LTM Mar 2026 | $368.3M USD | +18.2% | +6.7% | 51.4% | |
| LTM Feb 2026 | $146.03M USD | +12.9% | -3.6% | 46.5% | |
| LTM Mar 2026 | $137.69M USD | +28.8% | +30.1% | 57.8% | |
| LTM Mar 2026 | $19.82M USD | -5.8% | +123.9% | 6.6% | |
| LTM Mar 2026 | $15.51M USD | +24.0% | +26.7% | 38.2% | |
| LTM Dec 2025 | $9.24M USD | — | — | 8.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $1.25M USD | -45.8% | -51.6% | 12.8% |
| LTM Mar 2026 | $232K USD | — | — | 0.4% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding NNNN) | — | +18.2% | +16.0% | 46.3% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.43M | 23.54M | 6.71M | 8.19M | 9.76M |
| Cost of Revenue | 1.89M | 10.98M | 3.35M | 2.3M | 1.25M |
| Gross Profit | 2.54M | 12.56M | 3.36M | 5.89M | 8.51M |
| Gross Margin | 57.4% | 53.4% | 50.1% | 71.9% | 87.2% |
| Research & Development | 0 | 200K | 134.7K | 454.23K | 227.19K |
| Selling, General & Admin | 86.1K | 2.17M | 1.27M | 3.44M | 1.78M |
| Operating Expenses | 86.1K | 2.37M | 1.4M | 3.89M | 2M |
| Depreciation & Amortization | 0 | 6.25K | 13.04K | 0 | 0 |
| EBITDA | 2.54M | 10.03M | 2.27M | 2.57M | 6.51M |
| EBITDA Margin | 57.3% | 42.6% | 33.8% | 31.4% | 66.7% |
| Operating Income | 2.46M | 10.2M | 1.96M | 2M | 6.51M |
| Operating Margin | 55.5% | 43.3% | 29.2% | 24.4% | 66.7% |
| Interest Income | 0 | 42.25K | 165.34K | 337.51K | 160.28K |
| Interest Expense | 0 | 8K | 0 | 0 | 0 |
| Other Income / Expenses | 79.94K | (184.41K) | 292.78K | 377.48K | 717.46K |
| Income Before Tax | 2.54M | 10.01M | 2.25M | 2.37M | 7.23M |
| Pre-Tax Margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 2.54M | 10.01M | 2.25M | 2.37M | 7.23M |
| Net Margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% |
| EPS (Basic) | 0.03 | 0.07 | 0.02 | 0.06 | 0.16 |
| EPS (Diluted) | 0.03 | 0.07 | 0.01 | 0.06 | 0.16 |
| Weighted Avg Shares | 100M | 143.89M | 143.89M | 42.29M | 43.89M |
| Weighted Avg Shares (Diluted) | 100M | 143.89M | 187.78M | 42.29M | 43.89M |
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.